Navigation Links
Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
Date:5/14/2012

PRINCETON, N.J., May 14, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012.

Soligenix's revenues for the quarter ending March 31, 2012 were $647,418 as compared to $808,005 for the first quarter of 2011. The decrease in revenues was related to a reduction in reimbursable costs from the Company's Orphan Drug Grant covering a portion of its confirmatory Phase 3 clinical trial of orBec® in the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

Soligenix's net loss for the quarter ending March 31, 2012 was $1,438,755, or $(0.13) per share, as compared to $1,720,411, or $(0.16) per share for the quarter ending March 31, 2011, representing a decreased loss of $281,656. This decrease is primarily attributable to reduced spending resulting from the stoppage of the Phase 3 clinical trial of orBec® in acute GI GVHD.  This study was stopped in September 2011 and the Company has continued to incur minor costs associated with the close out of the clinical sites, data collection and analysis.

Research and development expenses for the quarter ending March 31, 2012 were $876,794 as compared to $1,372,804 for the quarter ending March 31, 2011. This decrease is primarily attributable to reduced spending in connection with the Phase 3 clinical trial of orBec®. General and administrative expenses for the quarter ending March 31, 2012 were $655,043, compared to $604,010 for the quarter ending March 31, 2011.

As of March 31, 2012, the Company's cash position was approximately $5,320,000 with working capital of approximately $4,440,000.   

Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "In the first quarter of 2012 we saw meaningful progress in our Vaccine/BioDefense business segment particularly with our
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
2. Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
3. Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
4. Soligenix Receives $574,000 in Non-Dilutive Financing from New Jerseys Technology Business Tax Certificate Transfer Program
5. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
6. Soligenix Reports Third Quarter 2011 Financial Results
7. Soligenix Announces Formation of Pediatric Crohns Disease Medical Advisory Board
8. Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD
9. Soligenix Reports Second Quarter 2011 Financial Results and Reviews Accomplishments
10. Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
11. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... antibodies for the treatment of autoimmune diseases, asthma and ... Yujiro S. Hata to its board of ... business and corporate development is a tremendous asset to ... and chief executive officer of Xencor. "Xencor faces a ...
(Date:7/30/2015)... 30, 2015 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today announced that Robert A. Ingram ... "Bob is an ardent champion for innovation in the ... have him on Edwards, board as we pursue our focused ... and CEO.  "Bob has provided a valuable perspective to our ...
(Date:7/30/2015)... VIEW, Calif. , July 30, 2015 ... it will release its second quarter 2015 financial results ... 2015.   In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
Breaking Medicine Technology:Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2
... Northern Ireland, Dec. 20, 2010 HeartSine Technologies ... the 14th annual Aisling Awards ceremony, November 25th, in ... who has made significant contributions to Belfast and surrounding ... the Belfast Media Group in 1997 to ...
... Calif., Dec. 20, 2010 Huntsman Gay Global Capital, ... the completion of a recapitalization of Sunquest Information Systems® ... recapitalization, led by Huntsman Gay, was done in partnership ... since 2007 and is retaining a significant stake in ...
Cached Medicine Technology:HeartSine Technologies Wins 2010 Aisling Award for Outstanding Achievement in Business 2Huntsman Gay-Led Consortium Completes Recapitalization of Sunquest Information Systems 2Huntsman Gay-Led Consortium Completes Recapitalization of Sunquest Information Systems 3
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional Products International, a company ... wellness products, announced the addition of Vincent Aquilino to its Board of Directors. ... and the prevention and rehabilitation of injuries, has spent the last 17-plus years ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... base, with the recent implementation of Microsoft Dynamics GP for a senior living ... Intellitec is now supporting senior living communities in 16 states. This further expansion ...
(Date:7/31/2015)... Orange, NJ (PRWEB) , ... July 31, 2015 ... ... obstructive sleep apnea (OSA) and the growing number of individuals who remain undiagnosed, ... of Americans continue to shy away from traditional CPAP therapy due to its ...
(Date:7/30/2015)... ... 31, 2015 , ... Reduce Human Error on the Drug ... and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice ... and device firms reduce manufacturing errors by 50 percent or more, will conduct ...
(Date:7/30/2015)... Dobbs Ferry, New York (PRWEB) , ... July 31, 2015 , ... ... President Barack Obama’s call to action by asking community members to contribute to the ... focused on, “Helping more of our young people stay on track. Providing the support ...
Breaking Medicine News(10 mins):Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3
... Comparative trials and observational studies previously conducted in ... These studies were performed before intracoronary stents and ... ,Therefore, Dr. Hanoch Hod, of Chaim Sheba ... followed 130 consecutive patients aged 70 or older ...
... vasectomy, contraception is typically left up to the woman. ... in a woman's contraceptive repertoire. Until now, men have ... searching for new options. Now, they may have one.// ... 12 percent. Vasectomies are considered permanent. Dr. Wang, of ...
... of choice for some doctors who think it's time to ... French physician invented it in the early 1800s. "The stethoscope ... allow you to distinguish between a heart that is beating ... ,"Sometimes the heart muscle is very weakened, but unless that ...
... spreads fast, and when it does, it can kill within months. ... tracks. ,Faith was more than a mere crutch for Rev. Jerry ... afraid of dying. My faith sustained me in that, but I ... highly curable if it's caught early, but it does not respond ...
... be found in water which has flowed through arsenic-rich ... drinking arsenic-rich water over long periods in countries world-wide. ... the earth's crust. ,Arsenic is introduced into water through ... groundwater //in some areas are elevated as a result ...
... affects women of child-bearing age, occurs when the the ... rendering them unable to produce eggs. PCOS symptoms include ... have said women// without these symptoms still can have ... though women's health experts caution that not every woman ...
Cached Medicine News:Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Arsenic in drinking water 2Health News:Arsenic in drinking water 3Health News:Arsenic in drinking water 4Health News:Arsenic in drinking water 5Health News:Arsenic in drinking water 6Health News:Arsenic in drinking water 7Health News:Arsenic in drinking water 8Health News:Polycystic Ovarian Syndrome(PCOS) linked to Diabetes 2
For use in cleaning soft contact lenses. Sensitive Eyes daily cleaner loosens and removes accumulations of film, deposits, and debris from soft contact lenses. Use with heat, chemical, and hydrogen p...
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
Renu rewetting drops soothe your eyes and moisturize soft contact lenses to minimize dryness....
Softwear Saline with unique comfort rinsing formula....
Medicine Products: